基于竞争特征的自主管理最近的葡萄糖监测设备的个性化选择
Olga Krylova1, Sevara Marchenko2, Alexandra Ermolaeva3
1Olga Krylova Associate Professor, Department of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Pakistan journal of medical sciences
|September 16, 2024
概括
本综述确定了用于糖尿病管理的葡萄糖监测设备的关键优势. 诸如非侵入性使用和改善患者遵守等特征对于有效的血糖控制至关重要.
科学领域:
- 医疗器械 医疗器械
- 糖尿病 技术 技术
- 生物医学工程 生物医学工程
背景情况:
- 糖尿病患病率的增加需要有效的血糖控制来预防并发症.
- 有广泛的葡萄糖监测设备 (GMDs),使患者的选择变得复杂.
- 对GMD的知情选择对于最佳的糖尿病管理至关重要.
研究的目的:
- 系统地审查和确定用于糖尿病患者血糖监测的医疗器械的竞争优势.
- 将各种GMD模型的优点分类,以帮助临床医生和患者选择设备.
主要方法:
- 系统的文献审查遵循SALSA标准和PRISMA指南.
- 在2023年2月16日至3月1日期间搜索了PubMed,IEEE Xplore,谷歌学者,CyberLeninka和eLibrary.
- 叙述,表格和视觉合成来自22个包含的手稿的结果.
主要成果:
- 确定了优势特征,包括非侵入性检查能力.
- 对于运动,听力和视力障碍患者来说,促进使用的设备是非常有益的.
- 软件和增强患者合规性的附加功能,特别是在儿科患者群体中,是有利的.
- 标记了提高分析速度和准确性的属性,同时没有阳效应.
结论:
- 系统地对GMD强度进行分类,有助于为糖尿病患者进行知情的设备选择.
- 专注于非侵入性功能,对受损患者的可用性以及增强合规性的技术是关键.
- 优化GMD选择有助于更好的血糖控制和预防并发症.
相关概念视频
01:15Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
01:06Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306